New medical advances could revolutionise the ability to treat undetected tuberculosis (TB) thanks to an international team of scientists led by the University of St Andrews.
Scientists at the School of Medicine are leading the medical monitoring of a new clinical trial to treat tuberculosis more quickly.
LifeArc and the Infection Group, led by Professor Stephen Gillespie announced a partnership to develop a molecular diagnostic test for the detection and quantification of tuberculosis (TB) bacteria in patients.
the first ever Molecular bacterial load assay (MBLA) stakeholders conference was held at the University of St Andrews, 11th – 13th June 2018.
Experts from around the world are gathered in St Andrews to learn how to dramatically cut the time needed to diagnose tuberculosis to save hundreds of thousands of lives.
Dr. Wilber Sabiiti recently presented a paper at the Keystone Symposia on Translation of tuberculosis research into policy and practice.
Dr. Wilber Sabiiti spent several days with the Porton Down PHE tuberculosis (TB) research team training them and optimising their Real-time PCR platform QuantiStudio TM Vii 6 and 7 Flex to perform Molecular bacterial load assay (MBLA).
Dr. Wilber Sabiiti recently presented some of his work at the UARC-TLD.
Hosted as part of the 6th East African Health and Scientific Research Conference and International trade fair the symposium was co-chaired by Dr. Wilber Sabiiti and Dr. Helen Meme of Kenya Medical Research Institute (KEMRI).
Dr Wilber Sabiiti has recently given a series of talks and training in different African countries showcasing the advantages of the molecular bacterial load assay (MBLA) and TWENDE work on developing model for rapid uptake of health research innovations into policy and practice.
- Page 1 of 2